Compare · NBIS vs TEM
NBIS vs TEM
Side-by-side comparison of Nebius Group N.V. (NBIS) and Tempus AI Inc. (TEM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NBIS and TEM operate in Computer Software: Programming Data Processing (Technology), so they compete in similar markets.
- NBIS is the larger of the two at $50.57B, about 4.1x TEM ($12.40B).
- NBIS has been more active in the news (17 items in the past 4 weeks vs 11 for TEM).
- TEM has more recent analyst coverage (25 ratings vs 23 for NBIS).
- Company
- Nebius Group N.V.
- Tempus AI Inc.
- Price
- -
- -
- Market cap
- $50.57B
- $12.40B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Computer Software: Programming Data Processing
- Computer Software: Programming Data Processing
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2011
- 2024
- News (4w)
- 17
- 11
- Recent ratings
- 23
- 25
Latest NBIS
- SEC Form 4 filed by Nebius Group N.V.
- Rosenblatt initiated coverage on Nebius Group N.V. with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Nebius Group N.V.
- SEC Form 4 filed by Nebius Group N.V.
- Chief Infrastructure Officer Korolenko Andrey sold $6,811,714 worth of Class A Shares (29,090 units at $234.16), decreasing direct ownership by 5% to 522,248 units (SEC Form 4) (for tax liability)
- Chief Technology Officer Shtan Danila sold $3,406,091 worth of Class A Shares (14,546 units at $234.16), decreasing direct ownership by 5% to 260,217 units (SEC Form 4) (withholding tax)
- CEO Volozh Arkadiy sold $8,846,096 worth of Class A Shares (37,778 units at $234.16), decreasing direct ownership by 5% to 785,236 units (SEC Form 4) to cover withholding tax
- AIB Data Centers to Present and Host One-on-One Meetings at the LD Micro 20th Annual Main Event on Wednesday, October 21, 2026
- SEC Form 6-K filed by Nebius Group N.V.
- Director Boynton John Wilson Iv sold $11,750 worth of Class A Shares (50 units at $235.01) as part of a pre-agreed trading plan, decreasing direct ownership by 0.01% to 410,782 units (SEC Form 4)
Latest TEM
- Tempus to Report Third Quarter 2026 Financial Results on November 2
- Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases
- Tempus Announces Multi-Year Collaboration with Moderna and Merck
- Amendment: SEC Form S-4/A filed by Tempus AI Inc.
- Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026
- CEO, Diagnostics Schoenherr Thomas Edward sold $873,885 worth of shares (10,281 units at $85.00) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 76,740 units (SEC Form 4)
- Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
- CEO and Chairman Lefkofsky Eric P sold $19,366,630 worth of shares (250,000 units at $77.47) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Tempus AI Inc.
- Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model